AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI. This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More
Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients. The international alliance will focus on leveraging the complementary capabilities, platforms and technologies from both partners, to accelerate… Read More
Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL… Read More
PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyses multi-modal datasets including… Read More
CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your… Read More
Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this new on-demand webinar we use multiple sclerosis as a case-study… Read More
Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Many of the most promising areas of drug development in this field target neuroinflammation and remyelination. In this on-demand webinar, presented by Dr Elise Malavasi, Principal Scientist at… Read More
Poolbeg Pharma and partner OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an artificial intelligence (AI) programme. The OneThree team, using its AI platform, identified novel drug targets using Poolbeg’s RSV human challenge trial data. The next… Read More
Kevin Holden Join DDW and Synthego for this free exclusive event today at 3pm GMT. Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery. Register now to hear speakers Kevin Holden and… Read More
The Psychiatry Consortium and the British Neuroscience Association recently published their ‘Guiding Principles for Robust Target Validation in Psychiatry’. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new… Read More
Kevin Holden In this webinar, hosted by DDW and supported by Synthego, Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery. Join this free exclusive event on 9 November at… Read More
Kevin Holden CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect… Read More
The latest DDW Sitting Down With sponsored podcast features Yuning Chen, Senior R&D Manager at Sino Biological. Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and… Read More
The latest DDW Sitting Down With sponsored podcast features Yuning Chen, Senior R&D Manager at Sino Biological. Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and… Read More
Kevin Holden Join this free exclusive event to find out more. It will take place on 9 November at 3pm GMT. CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that… Read More
Single cell and spatial tools from 10x Genomics are designed to deliver powerful, multiomic insights from complex disease samples that enable you to confidently fuel your target identification pipeline with the most promising candidates. Resolving complex biology with single cell and spatial multiomics will be presented… Read More
